Lineage withdraws CIRM grant application for OPC1 SCI trial; annual meeting results disclosed

Lineage Cell Therapeutics, Inc.

Withdrew CIRM CLIN2 grant application for OPC1 after receiving comments; says DOSED clinical study unaffected.
Shareholders elected all seven director nominees, including Michael Mulroy, Dipti Amin, and Deborah Andrews.
Ratified Baker Tilly as auditor for FY2026 (163.8M for, 0.7M against) and approved advisory say-on-pay (88.3M for, 2.6M against).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Lineage Cell Therapeutics, Inc. shareholders approved Advisory vote on the compensation paid to the Company’s named executive officers at the 2026-06-10 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

3. Shareholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as set forth in the Proxy Statement, by the following votes:

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Lineage Cell Therapeutics, Inc. shareholders approved Election of seven nominees to the board of directors at the 2026-06-10 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

1. Shareholders elected the seven nominees named below to the Company’s board to hold office until the Company’s 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Lineage Cell Therapeutics, Inc. shareholders approved Ratification of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

2. Shareholders ratified the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes:

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Lineage Cell Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-269557

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.